Mechanistic Studies of HIV exposed Seronegative Individuals (HESN) (R01) | Apply Online

Frequently Asked Questions (FAQs)

What is the "Mechanistic Studies of HIV Exposed Seronegative Individuals (HESN) (R01)" opportunity?

It was an NIH discretionary grant opportunity (Funding Opportunity Number PA-11-218) that supported hypothesis-driven research to explain why some people who are repeatedly exposed to HIV do not become infected and remain seronegative. The emphasis was on moving beyond observations and toward proven, causal mechanisms of protection.

What does HESN mean in this funding opportunity?

HESN refers to HIV-exposed seronegative individuals: people with repeated HIV exposure who nonetheless remain uninfected and test seronegative. The announcement also allowed studies of other clearly characterized groups that appear resistant to HIV infection.

What type of research did NIH want to fund under PA-11-218?

NIH sought mechanistic, hypothesis-driven studies designed to determine cause-and-effect explanations for apparent resistance to HIV infection. Projects were expected to test whether specific immune, genetic, mucosal, or cellular factors actually contribute to protection using rigorous experimental approaches.

What kind of applications were considered weak or not aligned with the announcement's intent?

Applications that were primarily descriptive or correlation-based (for example, reporting that a biomarker is higher or lower in HESN individuals without testing whether it is protective) were not aligned with the central emphasis of the opportunity, which prioritized mechanistic and causal evidence.

What does "mechanistic" mean in the context of this opportunity?

Mechanistic research, as described here, means studies that can demonstrate a protective mechanism at work rather than merely identifying associations. NIH signaled that strong proposals would include designs capable of distinguishing true protection mechanisms from confounding factors or chance findings.

What strategies were highlighted as ways to support causality rather than association?

The opportunity described approaches such as careful human cohort characterization combined with functional assays, experimental manipulation, and validation in independent populations, or other rigorous designs that can support causal conclusions about protective mechanisms.

What was the public health motivation for studying HESN individuals?

The motivation was to identify and prove natural mechanisms that block HIV acquisition in repeatedly exposed but uninfected people, so those insights could inform prevention tools such as vaccines, topical or systemic prophylaxis, microbicides, or immunotherapies that replicate the same protective biology.

What was the award mechanism for this opportunity?

The award mechanism was the NIH R01 research project grant, which generally supports substantial, multi-year investigator-initiated research projects.

Which NIH activity areas or program classifications were associated with this opportunity?

The program was tied to health research and listed under CFDA numbers 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research), reflecting its immunology and infectious disease focus related to HIV resistance.

Was cost sharing or matching required?

No. The opportunity did not require cost sharing or matching funds.

Who was eligible to apply?

Eligibility was broad and included many U.S. organization types and several non-U.S. options. Eligible applicants included state and local governments (including counties, cities/townships, special district governments, and independent school districts), federally recognized tribal governments and other tribal organizations, public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and other nonprofit statuses), public housing authorities/Indian housing authorities, and for-profit entities (including small businesses and other for-profits).

Did the opportunity include historically underserved or mission-focused institution types as eligible applicants?

Yes. The eligibility language explicitly included institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.

Were non-U.S. (foreign) organizations allowed to apply?

Yes. The announcement allowed non-domestic (non-U.S.) entities (foreign organizations), regional organizations, U.S. territories or possessions, and foreign components of U.S. organizations.

Why did the opportunity allow non-U.S. entities and foreign components?

The announcement reflected the reality that many high-exposure cohorts and key HIV prevention research settings are outside the continental United States, so it allowed foreign organizations and foreign components of U.S. organizations.

When was PA-11-218 posted, and what were the closing and archive dates?

The opportunity was posted and created on May 25, 2011. The original and final closing date was May 7, 2014, and the archive date was June 7, 2014.

Is this funding opportunity still open?

No. Based on the listed final closing date (May 7, 2014) and archive date (June 7, 2014), PA-11-218 is no longer open for applications under that specific announcement.

Where could applicants find the full funding announcement details?

NIH provided an additional information link to the full funding announcement on the NIH grants site for PA-11-218, which contained detailed requirements, scientific scope, and application instructions.

Who was the technical contact for issues accessing or linking to the announcement?

The contact listed for technical issues was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.

What was the central goal of the program in practical terms?

The central goal was to push the field beyond descriptive correlations and toward mechanistic, causal explanations, meaning proposals were expected to test whether candidate protective factors truly contribute to protection through rigorous experimental design.

What kinds of protective factors were explicitly mentioned as areas of interest?

The announcement explicitly referenced immune, genetic, mucosal, and cellular factors as potential contributors to protection that should be tested mechanistically.